Braxia Scientific Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Roger McIntyre

Algemeen directeur

CA$170.5k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	4.5yrs
Eigendom CEO	5.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Roger McIntyre's beloning veranderd ten opzichte van Braxia Scientific's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-CA$10m
Sep 30 2023	n/a	n/a	-CA$11m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	CA$238k	CA$238k	-CA$13m
Dec 31 2022	n/a	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$13m
Jun 30 2022	n/a	n/a	-CA$12m
Mar 31 2022	CA$300k	CA$300k	-CA$12m
Dec 31 2021	n/a	n/a	-CA$8m
Sep 30 2021	n/a	n/a	-CA$7m
Jun 30 2021	n/a	n/a	-CA$7m
Mar 31 2021	CA$277k	CA$277k	-CA$88m
Mar 31 2020	CA$119k	CA$119k	-CA$3m

Compensatie versus markt: De totale vergoeding ($USD 122.17K ) Roger } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 172.48K ).

Compensatie versus inkomsten: De vergoeding van Roger is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Roger McIntyre

4.5yrs

Tenure

CA$170,500

Compensatie

Dr. Roger S. McIntyre, MD., FRCPC., is Chief Executive Officer and Director of Braxia Scientific Corp. since May 11, 2020 and July 22, 2020 respectively and serves as its Chairman of the Board since Octobe...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roger McIntyre	Chairman & CEO	4.3yrs	CA$170.50k	5.17% CA$ 73.2k
Peter Rizakos	CFO & Director	less than a year	CA$134.04k	geen gegevens
Jerry Habuda	Independent Director	5.3yrs	geen gegevens	geen gegevens
Leann Taylor	Director	2.2yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van BRAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Braxia Scientific Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Recent updates

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Third quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 3Q 2023)

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.058 loss per share (vs CA$0.069 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.015 loss in 3Q 2022)

Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding

Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2022)

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp. Announces Court Approval of Class Action Settlement in Canada

Braxia Scientific Corp. Announces It Has Successfully Launched KetaMD in Florida

Braxia Scientific Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. (CNSX:BRAX) acquired 100% stake in KetaMD, Inc.

Full year 2022 earnings released: CA$0.069 loss per share (vs CA$0.56 loss in FY 2021)

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Braxia Scientific Corp. Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Certification and Hearing to Approve Proposed Settlement of Braxia Scientific Corp. Securities Class Action

High number of new and inexperienced directors

Braxia Scientific Corp. Announces Resignation of David Greenberg as Director

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Corp. Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

Braxia Scientific Corp. announced that it has received CAD 3 million in funding

Braxia Scientific Corp. announced that it expects to receive CAD 3 million in funding

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Comments on US Class Action

Braxia Scientific Corp. Launches Psilocybin-Assisted Clinical Therapy Training Program to Develop New Generation of Qualified Physicians, Psychotherapists and Psychologists for Mental Health

Braxia Scientific Corp. Receives Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression

Zhang Investor Law Announces Class Action Lawsuit on Behalf of Shareholders Who Bought Shares of Champignon Brands Inc

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur